This is a significant clinical catalyst that validates DISC-3405's mechanism and supports a path to pivotal trials. Traders should watch for the next data update (RESTORE-PV and sickle cell disease) and FDA feedback on selcodebart, both expected by year-end 2026. The stock is likely to re-rate higher on reduced pipeline risk.
IRON drugs
IRON drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 10 $74.14entry
- T+1 · 2mo ago −5.50%α −6.36% · $70.06
- T+5 · 2mo ago −6.69%α −6.19% · $69.18
- T+20 · 6w ago −18.03%α −20.16% · $60.77
- T+47 · todayOpen
- T+60 · in 17d Pending
Price Chart
How similar events traded
Executive Summary
Disc Medicine announced positive initial Phase 2 data for DISC-3405 in polycythemia vera (PV) at the SOHO conference. The drug demonstrated a significant reduction in phlebotomy events (from 4.0 to 0.6 over 26 weeks, p<0.0001), controlled hematocrit, and was well-tolerated. This is a strong clinical proof-of-concept for a novel mechanism in a large, underserved market (~150,000 US patients), de-risking the program and supporting advancement toward pivotal development.
Key Facts
- DISC-3405 reduced mean total phlebotomy events from 4.0 to 0.6 over 26 weeks (p<0.0001) in Cohort A.
- 61.5% of patients completing 26 weeks were entirely phlebotomy-free post-baseline.
- 77.8% of patients completing the first maintenance period (weeks 12-32) remained phlebotomy-free.
- Mean hematocrit was maintained stably below 45% through week 26.
- DISC-3405 was generally well-tolerated with mild, self-limited injection site reactions.
- The company plans to provide an update on RESTORE-PV and initial Phase 1b data in sickle cell disease by end of 2026.
- Disc also expects to share FDA end-of-Phase 2 feedback and plans for pivotal development of selcodebart in MF by year-end.
Financial Impact
Positive clinical data de-risks a pipeline asset targeting a ~150,000-patient US market. No financial figures were disclosed in the filing.
Risk Factors
- Data is from a small, open-label Phase 2 trial (n=13 completers in Cohort A) and may not replicate in larger, blinded studies.
- Competition from existing PV therapies (phlebotomy, cytoreductives) and other novel agents in development.
- Regulatory and commercial execution risk remains as the drug is still investigational.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-387351 |
| Document: iron-ex99_1.htm | 0001193125-26-387351 |
| Document: 0001193125-26-387351-index-headers.html | 0001193125-26-387351 |
| Document: 0001193125-26-387351-index.html | 0001193125-26-387351 |
| Document: 0001193125-26-387351.txt | 0001193125-26-387351 |
Track record
43 reports on IRON
7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
- Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
- Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
- Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
- Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
- Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers